home / stock / nrbo / nrbo quote
Last: | $3.14 |
---|---|
Change Percent: | 0.0% |
Open: | $3.06 |
Close: | $3.14 |
High: | $3.14 |
Low: | $3 |
Volume: | 16,907 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.14 | $3.06 | $3.14 | $3.14 | $3 | 16,907 | 04-26-2024 |
$3.06 | $3.05 | $3.06 | $3.16 | $3.0325 | 1,823 | 04-25-2024 |
$3.1 | $2.99 | $3.1 | $3.4999 | $2.99 | 39,253 | 04-24-2024 |
$3.02 | $3.1 | $3.02 | $3.19 | $2.99 | 42,194 | 04-23-2024 |
$3.12 | $3.26 | $3.12 | $3.3 | $3.08 | 23,389 | 04-22-2024 |
$3.37 | $3.49 | $3.37 | $3.49 | $3.26 | 20,562 | 04-19-2024 |
$3.44 | $3.59 | $3.44 | $3.59 | $3.3534 | 22,788 | 04-18-2024 |
$3.46 | $3.69 | $3.46 | $3.69 | $3.46 | 11,485 | 04-17-2024 |
$3.4 | $3.615 | $3.4 | $3.615 | $3.33 | 12,946 | 04-16-2024 |
$3.53 | $3.61 | $3.53 | $3.73 | $3.49 | 22,921 | 04-15-2024 |
$3.61 | $3.58 | $3.61 | $3.95 | $3.58 | 75,652 | 04-12-2024 |
$3.58 | $3.69 | $3.58 | $3.69 | $3.56 | 14,708 | 04-11-2024 |
$3.56 | $3.55 | $3.56 | $3.6648 | $3.5 | 13,047 | 04-10-2024 |
$3.53 | $3.93 | $3.53 | $3.93 | $3.47 | 47,568 | 04-09-2024 |
$3.97 | $3.8 | $3.97 | $3.97 | $3.7701 | 13,359 | 04-08-2024 |
$3.88 | $3.94 | $3.88 | $3.94 | $3.75 | 24,657 | 04-05-2024 |
$3.89 | $3.9 | $3.89 | $4.04 | $3.82 | 24,760 | 04-04-2024 |
$3.89 | $3.93 | $3.89 | $4.0699 | $3.8001 | 14,445 | 04-03-2024 |
$3.93 | $4.05 | $3.93 | $4.12 | $3.85 | 27,715 | 04-02-2024 |
$4.06 | $4.12 | $4.06 | $4.33 | $3.8 | 53,730 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the ...
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire Full Data Readout Expected in the Second Half of 2024 CAMBRIDGE, Mass. , April 1 , 2024 /PRNewswire/ -- Neur...
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update PR Newswire Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to ...